Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Magnetoencephalographic Correlates of Clinical Change After Cognitive Processing Therapy in Adults With PTSD (REC-HEALING-TR)

3. listopadu 2026 aktualizováno: Carmen Valiente Ots, Universidad Complutense de Madrid

REC-Healing Trauma: Clinical and Neurophysiological Mechanisms of Change in Cognitive Processing Therapy for Posttraumatic Stress Disorder. A Single-Arm Proof-of-Concept Pilot Study Using Magnetoencephalography

Cognitive Processing Therapy (CPT) is a first-line, evidence-based trauma-focused treatment for posttraumatic stress disorder (PTSD), but the clinical and neurophysiological mechanisms underlying therapeutic response remain poorly understood. This single-arm proof-of-concept pilot study will recruit 10 adults with active posttraumatic symptoms who will receive a 12-session 60 minutes individual CPT protocol. Before and after treatment, participants will undergo a clinical assessment and a magnetoencephalography (MEG) recording at the Center for Computational Cognitive Neuroscience (C3N-UCM). The study will test the feasibility of integrating MEG into a therapeutic process and explore whether changes in brain dynamics, particularly connectivity of cognitive-control and autobiographical-memory networks, are associated with clinical improvement.

Přehled studie

Detailní popis

Background: PTSD affects around 3.9% of the world population and is associated with impaired emotion regulation, interpersonal functioning and quality of life. CPT is recommended by major guidelines as a first-line treatment for PTSD (APA 2017, NICE 2018, WHO 2024, VA/DoD 2023). Its authors propose a neurobiological hypothesis in which PTSD involves amygdala hyperactivity and reduced frontal cortex activation, and in which the use of language during therapy would increase prefrontal activity while, simultaneously, reducing amygdala activity. To our knowledge, no study has examined the neurophysiological correlates of clinical improvement after CPT, whereas preliminary small studies exist for EMDR.

Design: Single-arm, quasi-experimental proof-of-concept pilot with pre- and post-treatment assessments.

Participants: Adults (≥ 18 years) with active PTSD symptoms who have been exposed to at least one traumatic event, attended at the University Psychology Clinic of the Universidad Complutense de Madrid (CUP-UCM) or referred to it by other social and health services. Target N = 10.

Intervention: A Spanish-adapted CPT protocol of 12 weekly individual 60-minute sessions in two phases: (1) worksheets and weekly assignments based on cognitive therapy, with psychoeducation, cognitive restructuring and Socratic dialogue; (2) continued work on five themes commonly affected by trauma: safety, trust, power/control, esteem and intimacy.

Assessment: Pre- and post-treatment (1) clinical assessment with a battery of psychometric instruments validated in Spanish; and (2) MEG recording at the Centro de Neurociencia Cognitiva y Computacional (C3N-UCM). Neurophysiological changes will then be correlated with clinical changes.

Context: The team has previous successful experience recruiting, delivering and assessing trauma-focused therapy in PTSD populations (Spanish Ministry of Science, Innovation and Universities grant PID2020-115003RB-I00).

Typ studie

Intervenční

Zápis (Odhadovaný)

10

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

  • Jméno: Javier Galgo Bendito, PhD student
  • Telefonní číslo: +34608011034
  • E-mail: jgalgo@ucm.es

Studijní místa

    • Madrid
      • Pozuelo de Alarcón, Madrid, Španělsko, 28223
        • Centro de Neurociencia Cognitiva y Computacional (C3N) ; Clínica Universitaria de Psicología (CUP-UCM)
        • Kontakt:
          • Carmen Valiente Ots, PhD
          • Telefonní číslo: +34913943135
          • E-mail: mcvalien@ucm.es
      • Pozuelo de Alarcón, Madrid, Španělsko, 28223
        • Clínica Universitaria de Psicología de la UCM
        • Kontakt:
          • Carmen Valiente Ots, PhD
          • Telefonní číslo: +34913943135
          • E-mail: mcvalien@ucm.es
        • Kontakt:
          • Javier Galgo Bendito, PhD Student
          • Telefonní číslo: +34 608011034
          • E-mail: jgalgo@ucm.es

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age ≥ 18 years.
  • Exposure to at least one traumatic event.
  • Active posttraumatic symptoms derived from that event (PCL-5 score above cut-off >= 30).

Exclusion Criteria

  • Active suicidal ideation at assessment (PHQ-9 item 9 and clinical judgment).
  • Substance dependence.
  • Severe cognitive impairment.
  • Concurrent trauma-focused individual or group psychotherapy (e.g., Prolonged Exposure, EMDR, CPT).
  • Contraindications for MEG: Metallic implants or active devices; claustrophobia.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Individual CPT with pre/post MEG

Participants receive 12 weekly individual sessions of CPT and undergo MEG and clinical assessment before and after treatment.

12 weekly 60-minute sessions; Spanish-adapted protocol based on Resick, Monson & Chard (2017); psychoeducation, cognitive restructuring, Socratic dialogue, weekly assignments; five themes: safety, trust, power/control, esteem and intimacy.

Recording at C3N-UCM before and after the intervention

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Feasibility of integrating MEG into CPT
Časové okno: Baseline and end of treatment (week 12)

Proportion of enrolled participants who complete the 12 sessions and both MEG recordings

Baseline and end of treatment (week 12)
Change in MEG Source-Space Functional Connectivity of Cognitive-Control and Autobiographical-Memory Networks During a Trauma Memory Cue Task at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Magnetoencephalography (MEG) will be recorded while participants perform a trauma memory cue task, adapted for MEG from the script-driven procedure used in the STAR mechanism study (Lanius et al., 2003; Whalley et al., 2013). Participants view personalised cues related to their trauma memory, contrasted with comparison cues. Functional connectivity (phase synchronisation between source-reconstructed regions of the cognitive-control and autobiographical-memory networks) will be estimated across canonical frequency bands. As this is the first MEG adaptation of the paradigm, the connectivity metric and bands are exploratory, with correction for multiple comparisons. The outcome is the change from baseline to week 12 in connectivity for the trauma versus comparison contrast.

Baseline and end of treatment (week 12)
Change in MEG Resting-State Source-Space Functional Connectivity of Cognitive-Control and Autobiographical-Memory Networks (Eyes-Open and Eyes-Closed) at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

MEG will be recorded during eyes-open and eyes-closed resting-state conditions. Functional connectivity (phase synchronisation between source-reconstructed regions of the cognitive-control and autobiographical-memory networks) will be estimated across canonical frequency bands, separately for each condition. The connectivity metric and bands are exploratory, with correction for multiple comparisons. The outcome is the change from baseline to week 12.

Baseline and end of treatment (week 12)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in PTSD/CPTSD symptoms (I) at 12 weeks
Časové okno: Baseline, at the beginning of each session, and end of treatment (week 12)

PTSD Checklist for DSM-5 (PCL-5; Weathers et al., 2013).

  • 20 items rated from 0 (not at all) to 4 (extremely). Total score ranges from 0 to 80.
  • Higher scores indicate a worse outcome (more severe symptoms).
Baseline, at the beginning of each session, and end of treatment (week 12)
Change in PTSD/CPTSD symptoms (II) at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

International Trauma Questionnaire (ITQ; Cloitre et al., 2018).

  • 12 symptom items (6 PTSD, 6 Disturbances in Self-Organization) rated from 0 (not at all) to 4 (extremely). Symptom total score ranges from 0 to 48 (each of the two sets of items from 0 to 24).
  • Higher scores indicate a worse outcome (more severe symptoms).
Baseline and end of treatment (week 12)
Change from psychopathological symptoms at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Symptom Assessment-45 Questionnaire (SA-45; Davison et al., 1997), a brief version of the Symptom Checklist-90-Revised (SCL-90-R).

  • 45 items rated from 0 (not at all) to 4 (a lot). It covers a total of 9 different symptomatic areas (e.g. depression, anxiety, interpersonal sensibility) and gives an overall severity score. Total score ranges from [0 to 180].
  • Higher scores indicate a worse outcome (more severe symptoms).
Baseline and end of treatment (week 12)
Change from Well-being at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Ryff's Scales of Psychological Well-Being (Ryff & Keyes, 1995).

  • 29 items rated from 1 (strongly disagree) to 6 (strongly agree). The SPWB evaluates 6 dimensions of psychological well-being: Self-acceptance, Positive relationships, Autonomy, Environmental mastery, Life purpose, and Personal growth. Scores ranges differ from scale to scale:
  • Self-acceptance [4-24]
  • Positive relationships [5-30]
  • Autonomy [6-36]
  • Environmental mastery [5-30]
  • Life purpose [4-24]
  • Personal growth [5-30]
  • Higher scores indicate a better outcome (more psychological wellbeing).
Baseline and end of treatment (week 12)
Change from Satisfaction with life at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Satisfaction with Life Scale (SWLS; Diener et al., 1985).

  • 5 items rated from 1 (strongly disagree) to 7 (strongly agree). Total score ranges from 5 to 35.
  • Higher scores indicate a better outcome (more satisfaction with life).
Baseline and end of treatment (week 12)
Change from Emotion Regulation at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Cognitive Emotion Regulation Questionnaire-short (CERQ-short; Garnefski & Kraaij, 2007).

  • 18 items rated from 1 (almost never) to 5 (almost always). The CERQ-short evaluates 9 dimensions (composed by 2 items each): Self-blame, Acceptance, Rumination, Positive refocusing, Refocus on planning, Positive reappraisal, Putting into perspectiva, Catastrophizing, and Other-blame. Each dimension ranges from 5 to 10. Also, two big dimensions are calculated depending on the type of strategy:
  • Sum of the adaptive subscales (acceptance, positive refocusing, refocus on planning, positive reappraisal, putting into perspective; 10 items) ranges from 10 to 50. Higher scores indicate a better outcome.
  • Sum of the maladaptive subscales (self-blame, rumination, catastrophizing, other-blame; 8 items) ranges from 8 to 40. Higher scores indicate a worse outcome.
Baseline and end of treatment (week 12)
Change from Self-care at 12 weeks
Časové okno: Baseline and end of treatment (week 12)

Self-Care Scale (Spanish instrument; "Escala de autocuidado", Gonzalez et al., 2017),

  • 31 items rated from 1 (completely disagre) to 7 (completely agree). The scale evaluates dimensions: Self-destructive behaviors, Non-tolerance towards positive affect, Issues accepting help, Resentment due to non-reciprocity, No positive activities, and None attendace towards personal needs.
  • Higher scores indicate worse self-care.
Baseline and end of treatment (week 12)
Client Satisfaction Questionnaire
Časové okno: Immediately after the intervention (week 12)

Acceptability will be assessed after the intervention using a participant satisfaction questionnaire (CSQ-8). The questionnaire will evaluate participants' perceived usefulness, relevance, comprehensibility, and overall satisfaction with the intervention. 8 items rated from 1 to 4. Total score ranges from 8 to 32. Higher scores indicate greater satisfaction and acceptability (better outcome).

Immediately after the intervention (week 12)
Change in neurophysiological measures at 12 weeks
Časové okno: Baseline to post-treatment (about 12 weeks)

Experimental task from the STAR trial, adapted to MEG. This task is designed to activate trauma-related autobiographical memories and contrast them with neutral memories. This paradigm probes how traumatic experiences are represented and contextualized in the brain. It has been adapted from previously validated script-driven trauma memory procedures used in neuroimaging studies of PTSD, which have consistently demonstrated sensitivity to trauma recall and associated neural responses (e.g., Lanius et al., 2003: Whalley et al., 2013).

Baseline to post-treatment (about 12 weeks)
Change from depression at 12 weeks
Časové okno: Baseline, at the beginning of each session, and end of treatment (week 12)

Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001).

  • 9 items rated from 0 (not at all) to 3 (nearly every day). Total score ranges from 0 to 27.
  • Higher scores indicate a worse outcome (more severe symptoms).
Baseline, at the beginning of each session, and end of treatment (week 12)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

15. ledna 2027

Primární dokončení (Odhadovaný)

15. ledna 2028

Dokončení studie (Odhadovaný)

15. července 2028

Termíny zápisu do studia

První předloženo

28. října 2026

První předloženo, které splnilo kritéria kontroly kvality

3. listopadu 2026

První zveřejněno (Aktuální)

4. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

4. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. listopadu 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit